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Background: HIV-associated neurocognitive disorders (HAND) exist in approximately 50% of infected individuals
even after the introduction of highly active antiretroviral therapy. HIV-1 Tat has been implicated in HIV-associated
neurotoxicity mediated through production of pro-inflammatory cytokines like IL-6 and IL-8 by astrocytes among
others as well as oxidative stress. However, the underlying mechanism(s) in the up-regulation of IL-6 and IL-8 are
not clearly understood. The present study was designed to determine the mechanism(s) responsible for IL-6 and
IL-8 up-regulation by HIV-1 Tat.
Methods: SVG astrocytes were transiently transfected with a plasmid encoding HIV-1 Tat. The HIV-1 Tat-mediated
mRNA and protein expression levels of both IL-6 and IL-8 in SVG astrocytes were quantified using real time RT-PCR
and multiplex cytokine assay respectively. We also employed immunocytochemistry for staining of IL-6 and IL-8.
The underlying signaling mechanism(s) were identified using pharmacological inhibitors and siRNA for different
intermediate steps involved in PI3K/Akt, p38 MAPK and JNK MAPK pathways. Appropriate controls were used in
the experiments and the effect of pharmacological antagonists and siRNA were observed on both mRNA expression
and protein levels.
Results: Both IL-6/IL-8 mRNA and protein showed peak expressions at 6 hours and 96 hours post-transfection,
respectively. Elevated levels of IL-6/IL-8 were also confirmed by immunocytochemistry. Our studies indicated that
both NF-kB and AP-1 transcription factors were involved in IL-6 and IL-8 expression mediated by HIV-1 Tat; however,
AP-1 was differentially activated for either cytokine. In the case of IL-6, p38δ activated AP-1 whereas JNK but not
p38 MAPK was involved in AP-1 activation for IL-8 production. On the other hand both PI3K/Akt and p38 MAPK
(β subunit) were found to be involved in activation of NF-κB that led to IL-6 and IL-8 production.
Conclusion: Our results demonstrate HIV-1 Tat-mediated induction of both IL-6 and IL-8 in a time-dependent manner
in SVG astrocytes. Furthermore, we also showed the involvement of NF-κB and AP-1 transcription factors regulated by
PI3/Akt, p38 MAPK and JNK MAPK upstream signaling molecules. These results present new therapeutic targets that
could be used in management of HAND.
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One of the hallmarks of neurodegeneration is inflamma-
tion in the central nervous system and dysregulation of
cytokines and chemokines has been attributed to this
process. Several pro-inflammatory cytokines, including
IL-1β, IL-6, IL-8 and TNF-α have been implicated in* Correspondence: kumaran@umkc.edu
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diseases including Alzheimer’s disease [1], Parkinson’s
disease (PD) [2], multiple sclerosis [3] and HIV-associated
neurocognitive disorders (HAND) [4]. In particular, ele-
vated levels of cytokines have been reported to correlate
with the degree of HAND [5]. While IL-6 and IL-8 have
been extensively studied for their role in Alzheimer’s dis-
ease and PD, not much is known about the role of these
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significantly reduced the incidence of HIV-associated
dementia (HAD), but increased the prevalence of less
severe forms of cognitive dysfunctions [6]. Many agents
have been implicated in leading to HAND, including
whole virus as well as viral proteins. The role of two
HIV proteins, HIV-1 Tat (trans activator of transcrip-
tion) and gp120 has been extensively studied for their
role in neuroinflammation. We and others have recently
shown that gp120 induces pro-inflammatory cytokines
and reactive oxygen species in different cells of the brain
and thereby contributes to HAND [7,8]. Likewise, HIV-1
Tat has also been shown to promote the release of several
pro-inflammatory cytokines and reactive oxygen species
from different brain cells [9,10].
HIV-1 Tat is an accessory viral protein produced at a
very early stage of HIV-1 replication and increases the
transcription of HIV-1 genome by greater than 100 fold
[11]. In addition to its role in replication, HIV-1 Tat has
also been shown to be involved in central nervous system
damage by various mechanisms, including the apoptosis
of the neurons by increasing the intracellular calcium
concentration and activation of the N-methyl-D-aspar-
tate receptors [12]. It also affects the function of dopa-
mine neurotransmission by deregulating the functions
of dopamine transporter and vesicular monoamine trans-
porter [13]. In addition to its direct effect on neurons,
HIV-1 Tat has been shown to exhibit a bystander effect
on neurons by promoting the release of several pro-
inflammatory cytokines/chemokines from astrocytes
and microglia [14,15]. HIV-1 Tat also affects the integrity
of the blood brain barrier by disrupting the tight junction
proteins in brain microvascular endothelial cells [16].
Astrocytes comprise the majority of cells in the brain
and also represent an important reservoir for the produc-
tion of various mediators of inflammation, particularly in
response to HIV-1 [17,18]. They play important roles in
many brain functions, including the modulation of neur-
onal activity and regulation of synaptic plasticity [19,20].
Post-mortem studies of brain samples of HIV-1-infected
patients showed that a small portion of astrocytes are re-
strictively infected with the virus [21]. In a previous study,
Churchill and colleagues have demonstrated extensive
astrocyte infection by HIV-1 in individuals suffering from
HAND [22]. In yet another independent study, it has been
shown that a sub-population of latently infected astrocytes
undergo apoptosis that correlates with the extent of HAND
[18]. HIV-1 Tat has not only been shown to be produced
by the HIV-1-infected astrocytes [23], but has also been
shown to promote the up-regulation of a variety of cyto-
kines/chemokines including MCP-1 (monocyte chemotac-
tic protein 1), IL-8, IL-6 and TNF-α [10,24,25].
Although HIV-1 Tat has been shown to induce IL-6
and IL-8 in astrocytes, the mechanism(s) remains largelyunknown. The present study was undertaken to ascer-
tain underlying mechanism(s) for IL-6 and IL-8 cytokine
expressions with the idea of identifying transcription fac-
tors and upstream signaling molecules.
Materials and methods
Cell culture and reagents
Experiments were performed using SVG astrocytes, ori-
ginally developed by Dr. Eugene Major and colleagues
and primary astrocytes (obtained from BDRL, Seattle,
WA, USA). The cells were cultured in DMEM supple-
mented with sodium bicarbonate, non-essential amino
acids, L-glutamine, fetal bovine serum and gentamicin
and were maintained in an incubator at 37°C and humidi-
fied air with 5% CO2. HIV-1 Tat expression plasmid, ini-
tially developed by Dr. E Verdin, Gladstone institute,
UCSF (catalog # 10453), and HIV-1 Tat protein (catalog #
2222) were obtained from the NIH AIDS reagent pro-
gram. All the pharmacological inhibitors were purchased
from Cayman Chemical Company (Ann Arbor, MI, USA).
siRNA against p38 isoforms (α/β/γ/δ), p50, p65 and nega-
tive silencer1 (scrambled) were purchased from Ambion
Inc. (Carlsbad, CA, USA). siRNA against Akt isoforms
(1/2/3), AP-1 (c-jun), C/EBPα and C/EBPγ were pro-
cured from Thermo Fisher Scientific (Pittsburgh, PA,
USA). The primary antibodies for p65, p-c-jun, glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) and all
the secondary antibodies were purchased from Cell
Signaling (Danvers, MA, USA) and primary antibodies
for p-p38, p-Akt, p-JNK and LaminB were purchased
from Santa Cruz Biotechnology (Dallas, TX, USA).
Transfection
SVG astrocytes were transiently transfected with HIV-1
Tat plasmid by using Lipofectamine 2000 (Life Technolo-
gies, NY, USA) as previously described [26]. Briefly, astro-
cytes were plated in a 6- or 12-well plate and allowed to
adhere overnight. The complete DMEM was removed the
following day and the cells were washed twice with PBS
and serum free DMEM was added to the wells. A trans-
fection mixture containing Lipofectamine and Optimem
with or without HIV-1 Tat plasmid was added to the wells.
After 5 hours, the transfection mixture was replaced
with complete DMEM. For experiments involving pharma-
cological inhibitors, cells were pretreated 1 hour prior to
the transfection. For experiments involving siRNA, the cells
were transfected with siRNA for 48 hours before transfec-
tion with HIV-1 Tat plasmid to ensure optimum knock
down.
Real time RT-PCR and multiplex cytokine assay
RNA was extracted from the SVG astrocytes using
RNeasy kit from Qiagen (Valencia, CA, USA) as recom-
mended by the manufacturer. Primer sequences and
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previously [7,27]. The expression levels of these cytokines
were normalized with hypoxanthine phosphoribosyl trans-
ferase. The fold expression of cytokines was calculated
using the 2-ΔΔct method.
The protein concentrations of IL-6 and IL-8 in the
culture supernatants were determined by multiplex cyto-
kine assay. The detailed protocol has been published previ-
ously [26]. Briefly, 50 μL of the supernatants or standards
are added to a pre designed 96-well plate containing
magnetic beads. After incubation for 30 minutes at
room temperature, 25 μL of detection antibody are
added to each well. Then wells were washed and 50 μL
of streptavidin-PE conjugate is added and incubated
for 10 minutes, followed by washing and adding assay
buffer. The concentrations of IL-6 and IL-8 were deter-
mined and analyzed by Bio-Plex manager 5 software using
5-PL statistics (Bio-Rad, Hercules, CA, USA).
Western blot
SVG astrocytes were harvested and whole cell lysates as
well as cytoplasmic and nuclear extracts were prepared
as needed. For whole cell extract preparation, radioim-
munoprecipitation assay (RIPA) buffer was used to lyse
the cells, followed by homogenization and spinning at
10,000 rpm for 10 minutes to remove the cell debris. For
nuclear and cytoplasmic extracts, the cells were trypsi-
nized and centrifuged at 10,000 rpm for 5 minutes.
The cell pellet was resuspended in 300 μL of cytoplas-
mic extraction reagent, followed by incubation on ice
and washing with PBS. Then 200 μL of nuclear extraction
reagent were added and the cell pellet was incubated on
ice for 15 minutes to collect the nuclear portion. The con-
centrations of the proteins were determined from the
standard curve using the BCA kit (Pierce Biotechnology,
Rockford, IL, USA). Twenty micrograms of protein sam-
ple were loaded into the wells of 12% polyacrylamide gel
and the sample was electrophoresed at 80 V for 3 hours
followed by transfer onto a polyvinylidene fluoride (PVDF)
membrane for 90 minutes at 350 mA. The membrane was
blocked in 5% nonfat dry milk for 1 hour. The membranes
were incubated in primary antibody overnight at 4°C. The
membranes were washed with PBST and incubated in the
appropriate horseradish peroxidase (HRP)-conjugated
secondary antibody for 90 minutes. The membranes
were again washed with PBST and the proteins were visu-
alized by using BM Chemiluminescence Western Blotting
Substrate (POD) (Roche Applied Sciences, Indianapolis,
IN, USA). The bands were analyzed and quantified by
Fluorchem HD2 software (Alpha Innotech, San Leandro,
CA, USA). GAPDH and LaminB were used as internal
loading controls for cytoplasmic and nuclear protein,
respectively, to normalize the expression of proteins of
interest.Immunocytochemistry
SVG astrocytes were plated in a 12-well plate with cover
slips and were allowed to adhere overnight. Next morning,
complete DMEM was replaced by DMEM without serum
and cells were transfected with the plasmid encoding
HIV-1 Tat for 24 hours. Golgi stop (1 mg/ml) was added 6
hours before the termination of transfection to prevent
the release of IL-6 and IL-8 from astrocytes. The cells
were fixed in 1:1 solution of ice-cold acetone and
methanol for 20 minutes and were allowed to air dry
for 5 minutes. The cells were washed with PBST and
blocked with 1% BSA in PBST for 30 minutes. Then
the cells were incubated overnight with a mixture of
primary antibodies, including mouse anti-glial fibrillary
acidic protein (anti-GFAP) (1:1,000) and either rabbit anti-
IL-6 or rabbit anti-IL-8 (1:500). The cells were washed
thrice with PBST and incubated with a mixture of second-
ary antibodies containing Alexafluor 488 labeled anti-
rabbit IgG and Alexafluor 555 labeled anti-mouse IgG
at a dilution of 1:1,000. After incubating the cells in the
dark for 1 hour, the cells were washed thrice with
PBST and the cover slips were mounted on a glass slide
containing 4′,6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories, Burlingame, CA, USA). The images were ac-
quired using inverted confocal microscope, Leica TCS SP5
II (Leica Microsystems, Wetzler, Germany). ImageJ soft-
ware was used to analyze the images and calculate the in-
tensity values by using GFAP as housekeeping gene.
Statistical analysis
The statistical significance for the time kinetics experiments
was calculated using Student’s t-test. For all the experi-
ments involving the use of pharmacological antagonists and
siRNA, one-way analysis of variance (ANOVA) was used
to calculate the statistical significance. All the experiments
were performed in triplicates and the results are repre-
sented by the mean ± standard error (SE) of at least three
independent experiments. A P-value of ≤ 0.05 was consid-
ered to be statistically significant.
Results
HIV-1 Tat induces a time-dependent expression of IL-6
and IL-8 in astrocytes
In the present study, we first sought to confirm the earlier
finding that HIV-1 Tat up-regulates IL-6 and IL-8 expres-
sion in astrocytes. The SVG astrocytes were transfected
with a plasmid encoding HIV-1 Tat and the transfection
efficiency was monitored by setting a parallel transfection
with a plasmid encoding green florescent protein [27].
The efficiency as measured and analyzed by flow cyto-
metry ranged between 50 to 65% (data not shown). We
first performed a time kinetics experiment to determine
the peak expression levels of IL-6 and IL-8 at mRNA and
protein levels. Compared to mock-transfected cells, the
Nookala and Kumar Journal of Neuroinflammation  (2014) 11:214 Page 4 of 18levels of IL-6 and IL-8 mRNA increased as early as 1 hour,
peaked at 6 hours and declined steadily until 72 hours
(Figure 1a, d). The peak expression levels of IL-6 and IL-8
after 6 hours of transfection was found to be 29.2 ± 2.5
and 26.2 ± 1.7 fold, respectively.
To determine the protein levels of these cytokines, a
multiplex cytokine assay was performed at indicated
time points (6, 12, 24, 48, 72 and 96 hours). The levels
of IL-6 protein started to increase significantly from 6
hours (6.10 ± 0.36 ng/ml versus 2.10 ± 0.19 ng/ml) after
transfection and gradually increased until 96 hours (14.08
± 1.59 ng/ml versus 1.79 ± 0.22 ng/ml) where it showed
the maximum increase (until observation period) com-
pared to the mock-transfected cells (Figure 1b). Similar to
IL-6, the protein expression of IL-8 has also started to in-
crease significantly from 6 hours (0.172 ± 0.01 compared
to 0.112 ± 0.006 ng/ml in controls) and showed a progres-
sive increase in protein expression until 96 hours (0.813 ±
0.09 ng/ml compared to 0.185 ± 0.005 ng/ml in controls)
(Figure 1e). There was no significant change in IL-6 and
IL-8 protein levels in mock-transfected cells. These results
clearly demonstrate that HIV-1 Tat induces the expres-
sion of IL-6 and IL-8 from astrocytes in a time-Figure 1 HIV-1 Tat induces time dependent expression of IL-6 and
were transfected with 0.3 μg of HIV-1 Tat plasmid using Lipofectamine 2
and total RNA was isolated. The expression levels of IL-6 and IL-8 were d
normalized to their mock-transfected controls. (b, e) The concentrations
24, 48, 72 and 96 hours after transfection by multiplex cytokine assay. O
mock- and HIV-1 Tat- transfected cells, respectively. Each experiment wa
individual experiments. (c, f) Primary astrocytes from 2 independent don
RNA was isolated. The expression levels of IL-6 and IL-8 were determine
Student’s t-test and ** denotes P-value of ≤ 0.01.dependent manner at mRNA as well as protein level.
These results were also confirmed in primary astro-
cytes isolated from 2 fetal brains collected after abor-
tion where treatment with HIV-1 Tat protein (200 ng/ml)
for 2 hours showed significant IL-6 and IL-8 up-regulation
(Figure 1c, f ).
Immunocytochemistry was performed to determine
the presence of elevated levels of IL-6 and IL-8 proteins
inside the cell when they are transfected with HIV-1 Tat
plasmid (Figure 2). The results clearly show that both
IL-6 and IL-8 are increased in HIV-1 Tat-transfected
cells when compared with mock-transfected and un-
transfected cells (Figure 2h, 2r). Our results also indicate
that astrocyte marker GFAP did not significantly change
with either control or mock or HIV-1 Tat transfection
(Figure 2a, d, g, k, n, q). The intensity of IL-6 over GFAP
was 3 ± 0.21 fold higher in HIV-1 Tat-transfected cells
when compared to the control cells (Figure 2j). Simi-
larly, the intensity of IL-8 was 2.46 ± 0.28 fold more
when compared to the untransfected cells (Figure 2t).
The change in intensities of either IL-6 or IL-8 was not
significant in mock-transfected cells when compared to
the untransfected cells.IL-8 in SVG astrocytes. Seven hundred thousand SVG astrocytes
000. (a, d) Cells were harvested at 1, 3, 6, 12, 24, 48 and 72 hours
etermined by real time RT-PCR. The values represented are
of IL-6 and IL-8 in cell culture supernatants were measured at 6, 12,
pen bars and closed bars represent protein concentrations of
s done at least in triplicate and each bar represents the ± SE of three
ors were treated with 200 ng/ml of Tat protein for 2 hours and total
d by real time RT-PCR. Statistical analyses was performed by
Figure 2 Immunocytochemistry of IL-6 and IL-8 mediated by HIV-1 Tat in astrocytes. (a-i, k-s) Five hundred thousand SVG astrocytes were
grown on a cover slip and transfected with plasmid encoding HIV-1 Tat. The over expression of IL-6 and IL-8 by HIV-1 Tat (g-i, q-s) was compared
with control cells (a-c, k-m) and mock-transfected cells (d-f, n-p). The cells were costained with a mixture of antibodies against GFAP (red) and
either IL-6 or IL-8 (green). The nucleus was stained blue using 4′,6-diamidino-2-phenylindole (DAPI). The images for different fluorophores were
obtained using an inverted confocal microscope. The quantification of IL-6 and IL-8 were done using imageJ software (j, t). Each experiment was
done at least in triplicate and each bar represents the ± SE of three individual experiments. Statistical analyses was performed by Student’s t-test
and ** denotes P-value of≤ 0.01.
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NF-κB pathway
NF-κB is a crucial transcription factor involved in many
inflammatory processes, including the up-regulation of
several pro-inflammatory cytokines. Previous reports
from our group and others have demonstrated the role
of NF-κB in the production of cytokines by HIV-1 Tat
in astrocytes and other cells [26,28]. We performed time
kinetics to determine the peak increase in p65 trans-
location (indicator of NF-κB activation). Compared to
mock-transfected cells, p65 translocation in HIV-1 Tat-
transfected cells started to increase as early as 3 hours,
peaked at 9 hours and remained constant until 12 hours
(Figure 3a). We also confirmed the involvement of NF-
κB in primary astrocytes from two different donors by
measuring p-IκBα expression after treatment with HIV-1
Tat protein. The level of p-IκBα increased as early as 5
minutes and peak level was observed at 20 minutes
post-treatment (Figure 3b).After establishing that HIV-1 Tat-induced p65 trans-
location with HIV-1 Tat in SVG astrocytes, we wanted
to determine if NF-κB was involved in up-regulation of
IL-6 and IL-8 cytokines. For this, we first used a
pharmacological inhibitor. Cells were pretreated with
10 μM concentration of specific inhibitory kinase kin-
ase (IKK) inhibitor, BAY11-7082 1 hour prior to trans-
fection with HIV-1 Tat. The levels of IL-6 and IL-8
were determined at 6 hours and 48 hours post transfec-
tion for mRNA and protein respectively. BAY11-7082
decreased the expression of IL-6 by 47.1 ± 6.1% and
63.3 ± 4.7% at mRNA and protein levels respectively
(Figure 3c, e). Similarly, the expression levels of IL-8
were decreased by 41.1 ± 7.5% and 47.4 ± 4.7% at the
levels of mRNA and protein respectively (Figure 3d, f ).
We also measured the translocation of p65 into the nu-
cleus upon pretreatment with BAY11-7082. The trans-
location of p65 decreased by 32 ± 3.3% compared to the
HIV-1 Tat-transfected cells (Figure 3g). To confirm the
Figure 3 (See legend on next page.)
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Figure 3 Involvement of NF-κB in HIV-Tat mediated up-regulation of IL-6 and IL-8. (a) SVG astrocytes were either mock-transfected or
transfected with HIV-1 Tat plasmid and translocation of p65 was measured at 3, 6, 9 and 12 hours. Open bars and closed bars represent cytoplasm
and nuclear fractions, respectively. (b) Primary astrocytes were treated with 200 ng/ml Tat protein and p-IκBα protein levels were measured from
0 minutes to 60 minutes. The bar graph represents the mean values obtained from two independent donors. (c-g) Astrocytes were pretreated
with 10 μM concentration of NF-κB inhibitor (BAY11-7082) 1 hour prior to the transfection. The expressions of IL-6 and IL-8 were determined at 6
hours and 48 hours post transfection for mRNA (c, d) and protein (e, f), respectively. The values represented are normalized their mock-transfected
controls. (g) Astrocytes were either mock-transfected or transfected with HIV-1 Tat plasmid for a duration of 6 hours and translocation of p65 was
measured. (h-k) Astrocytes were transfected with siRNA (scrambled or p65 or p50) for 48 hours, followed by transfection with HIV-1 Tat plasmid. The
expression of IL-6 and IL-8 was determined at 6 hours and 48 hours post transfection for mRNA (h, i) and protein (j, k), respectively. Each experiment
was done at least in triplicate and each bar represents the ± SE of three individual experiments. Statistical analyses was performed by one-way ANOVA
and ** denotes P-value of≤ 0.01.
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siRNA approach to individually knock down major
subunits of NF-κB which include p50 (NF-κB1) and
p65 (RelA) subunits. We have previously verified the
efficiency of knock down of individual siRNA [29]. Our
results show that p65, but not p50 knock down decreased
the expression of IL-6 by 40.8 ± 3.8% and 48.2 ± 5.8% at
mRNA and protein levels respectively (Figure 3h, j). Simi-
lar to the inhibitor results, knock down of p65 decreased
the expression levels of IL-8 by 60.1 ± 4.7% at the level
of mRNA and by 69.3 ± 2.6% at the level of protein
(Figure 3i, k). Knock down of the p50 subunit of NF-κB
did not affect the expression levels of IL-6 and IL-8 at
either level of mRNA or protein. Knock down of p50
subunit of NF-κB did not have any effect on the expres-
sion levels of IL-6, but has increased the expression levels
of IL-8 at mRNA and protein.
HIV-1 Tat-mediated induction of IL-6 and IL-8 involves
p38 MAPK pathway
After establishing the role of NF-κB, we wanted to explore
the role of upstream signaling molecules that could ac-
tivate NF-κB. p38 mitogen activated-protein kinase
(p38 MAPK) is a family of important upstream MAPKs
that can activate NF-κB and regulate the expression of
many cytokine/chemokines. To determine the role of
p38 MAPK in the up-regulation of IL-6 and IL-8 by
HIV-1 Tat, we used SB203580, a specific inhibitor of
p38 MAPK. Pretreatment of astrocytes with 10 μM
concentration of SB203580 decreased the expression
levels of IL-6 by 47.8 ± 4.1% and 82.4 ± 0.5% at levels of
mRNA and protein respectively (Figure 4a, c). Similarly,
pretreatment with SB203580 decreased the expression
levels of IL-8 by 43.2 ± 5.6% and 66.1 ± 5.8% at the at
mRNA and protein levels (Figure 4b, d). The involvement
of p38 MAPK was further confirmed by the fact that HIV-
1 Tat-mediated increase in phosphorylated p38 levels were
decreased by pretreatment with SB203580 (Figure 4e).
p38 MAPK exists in four different isoforms (α/β/γ/δ)
of which SB203580 affects only p38α and p38β isoforms
of p38 but not the other two isoforms (p38γ and p38δ).In order to validate the roles of p38α and p38β and also
to determine the roles of the other two isoforms in the
up-regulation of IL-6 and IL-8, we individually knocked
down all the isoforms of p38 (α/β/γ/δ) using siRNA. The
gene knock down was generally partial (>60%) except in
the case of p38β where silencing was complete [29,30].
Knocking down p38β and p38δ isoforms decreased the
expression of IL-6. Specifically, knock down of p38β
decreased the expression of IL-6 by 42.6 ± 5.6% and
41.4 ± 4.9% at the levels of mRNA and protein, respect-
ively (Figure 5a, c). Further, p38δ knock down decreased
the expression of IL-6 by 49.7 ± 3.5% and 43.8 ± 4.3% at
mRNA and protein levels respectively (Figure 5a, c). Indi-
vidual knock down of only p38β decreased the expression
level of IL-8 by 47.1 ± 6.4% and 36.2 ± 6.4% at the level of
mRNA and protein respectively (Figure 5b, d). Of all the
p38 isoforms, p38α and p38β are known to activate NF-
κB. To see if p38 MAPK was leading to the activation of
NF-κB, we pretreated the astrocytes with SB203580 and
measured p65 translocation into the nucleus. Pretreat-
ment with SB203580 decreased the translocation of p65
by 33.9 ± 4.6% compared to HIV-1 Tat-transfected astro-
cytes (Figure 4f). To specifically determine if p38β isoform
led to the activation of NF-κB in our model system, we
individually knocked down p38β isoform with siRNA
and measured the translocation of p65 into the nucleus.
Knocking down p38β isoform decreased p65 translocation
by 28.5% ± 3.6% compared to HIV-1 Tat- transfected cells
(Figure 5e).
HIV-1 Tat-mediated induction of IL-6 and IL-8 involves
AP-1 transcription factor activated by different upstream
signaling molecules
In view of our results that p38δ knock down decreased
IL-6 expression; we wanted to determine the possible
transcription factors that could be activated by p38δ. Ac-
tivator protein-1 (AP-1) and CCAT enhancer binding
proteins (C/CAT), specifically C/EBPα and C/EBPγ are
known to be activated by p38δ. To ascertain the involve-
ment of these transcription factors in the up-regulation
of IL-6 and IL-8 by HIV-1 Tat, we individually knocked
Figure 4 (See legend on next page.)
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Figure 4 Inhibition of HIV-1 Tat-induced expression of IL-6 and IL-8 by inhibitors of p38 mitogen activated-protein kinase (MAPK). (a-f)
Astrocytes were pretreated with 10 μM concentration of p38 MAPK inhibitor (SB203580) 1 hour prior to the transfection. (a, b) The expression
levels of IL-6 and IL-8 at mRNA were determined by real time RT-PCR at 6 hours post transfection. The values represented are normalized to their
mock-transfected controls. (c, d) The protein concentrations of IL-6 and IL-8 were determined in the cell culture supernatants at 48 hours post
transfection by multiplex cytokine assay. (e) Astrocytes were either mock-transfected or transfected with HIV-1 Tat plasmid for a duration of 6
hours and p-p38 levels were measured in whole cell extracts. (f) Astrocytes were either mock-transfected or transfected with HIV-1 Tat plasmid
for duration of 6 hours and translocation of p65 was measured. A representative Western blot is shown in panels (e) and (f). Each experiment
was done at least in triplicate and each bar represents the ± SE of three individual experiments. Statistical analyses was performed by one-way
ANOVA and ** denotes P-value of≤ 0.01.
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but not C/EBPα or C/EBPγ knock down by siRNA de-
creased the IL-6 expression by 43.2 ± 3.4% and 51.2 ± 6.3%
at mRNA and protein level, respectively (Figure 6a, c).
The role of AP-1 in IL-6 induction was further confirmed
by time-dependent increase in expression of p-c-jun in
both SVG astrocytes and primary astrocytes after expos-
ure with HIV-1 Tat (Additional file 1: Figure S1A, B). To
demonstrate that p38δ leads to the activation of AP-1, we
knocked down p38δ and measured the levels of p-c-jun.
Knocking down p38δ decreased the p-c-jun levels in the
cells transfected with HIV-1 Tat by 30.8% ± 2.1% and
scrambled siRNA did not have any effect on the p-c-jun
levels (Figure 5f).
Surprisingly, knocking down AP-1 transcription fac-
tor decreased the levels of IL-8 by 42.1 ± 8.4% and
44.3 ± 3.2% at the levels of mRNA and protein, respect-
ively (Figure 6b, d). We next wanted to explore the other
possible upstream signaling molecules that can be in-
volved in the activation of AP-1. C-Jun N-terminal kin-
ase (JNK) is another upstream signaling molecule that
can activate AP-1. To determine the role of JNK in the
up-regulation of IL-8 in astrocytes by HIV-1 Tat, we
pretreated cells with a specific JNK inhibitor (SP600125)
and measured the levels of IL-8 at 6 hours and 48 hours
for mRNA and protein, respectively. Pretreatment with
SP600125 decreased the levels of IL-8 by 42.4 ± 9.0%
and 58.3 ± 7.0% at mRNA and protein levels, respectively
(Figure 7b, d). We pretreated astrocytes with SP600125
and measured the phosphorylation of JNK to verify the
activation of JNK MAPK by HIV-1 Tat. Pretreatment with
SP600125 decreased the HIV-1 Tat-mediated increase in
phosphorylated JNK (Figure 7e). Next, to determine
whether JNK MAPK can lead to the activation of AP-1
transcription factor, we pretreated the astrocytes with
SP600125 and measured the phosphorylation of c-jun.
As shown in Figure 7f, densitometric analysis of Western
blot shows that pretreatment with SP600125 decreased
the levels of p-c-jun by 28.3 ± 3.3% compared to the HIV-
1 Tat-transfected cells. To confirm the role of JNK MAPK
in the activation of AP-1, we specifically knocked down
JNK1 isoform using siRNA and measured the phosphory-
lated c-jun levels. Knock down of JNK1 decreased p-c-junlevels by 26.1 ± 5.2% compared to HIV-1 Tat-transfected
cells (Figure 7g).
Up-regulation of IL-6 and IL-8 by HIV-1 Tat involves
PI3K/Akt pathway
After determining the involvement of NF-κB and MAPK
regulators in the up-regulation of IL-6 and IL-8, we wanted
to explore the role of further upstream signaling molecules
that can activate NF-κB. The phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K)/Akt pathway is a major
upstream signaling mechanism that is involved in the
regulation of cytokines by activation of NF-κB through
IκB kinase (IKK)-mediated phosphorylation of IκBα [31].
To ascertain the role of PI3K/Akt in the up-regulation
of IL-6 and IL-8 cytokines by HIV-1 Tat, we initially
employed an inhibitor approach wherein the cells were
pretreated with LY294002, a reversible PI3K inhibitor.
LY294002 decreased HIV-1 Tat-mediated expression of
IL-6 by 73.5 ± 2.6% and 81.3 ± 0.7% at the levels of
mRNA and protein, respectively (Figure 8a, c). IL-8 was
also decreased by 43.3 ± 3.5% and 55.1 ± 1.9% at mRNA
and protein levels, respectively (Figure 8b, d). HIV-1
Tat-mediated increase in phosphorylated Akt levels were
decreased by pretreatment with LY294002 (Figure 8e).
Activation of NF-κB by PI3K was determined by meas-
uring the translocation of p65 upon pretreatment with
LY294002. Compared to HIV-1 Tat-transfected cells,
pretreatment with LY294002 decreased the transloca-
tion of p65 by 29.9 ± 5.9% (Figure 8f ). In order to con-
firm the results of a pharmacological antagonist, we
employed the siRNA approach to individually knock
down immediate downstream effector signaling mole-
cules, including Akt1, Akt2 and Akt3. Individual knock
down of all the isoforms decreased the expression
levels of IL-6 and IL-8 by 35% and 30%, respectively at
mRNA level (Figure 8g, h). Similar results were obtained
at protein level, where the decrease for IL-6 and IL-8 was
found to be 35% and 28%, respectively (Figure 8i, j).
Discussion
Several mechanisms, including the dysregulation of the
cytokine profile and infiltration of various inflammatory
cells have been proposed for the development of HAND
Figure 5 (See legend on next page.)
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Figure 5 Involvement of p38 mitogen activated-protein kinase (MAPK) in the induction of IL-6 and IL-8 by HIV-1 Tat. (a-f) SVG
astrocytes were transfected with siRNA (scrambled or p38α or p38β or p38γ or p38δ) for 48 hours. Then they are mock-transfected or transfected
with plasmid encoding HIV-1 Tat. (a, b) The expression levels of IL-6 and IL-8 at mRNA were determined by real time RT-PCR at 6 hours post
transfection. The values represented are normalized to their mock-transfected controls. (c, d) The protein concentrations of IL-6 and IL-8 were
determined in the cell culture supernatants at 48 hours post transfection by multiplex cytokine assay. (e) Astrocytes were transfected with p38β
siRNA for 48 hours prior to transfection with HIV-1 Tat plasmid. The translocation of p65 is measured 6 hours after transfection. Open bars and
closed bars represent cytoplasm and nuclear fractions, respectively. (f) Astrocytes were transfected with p38δ siRNA for 48 hours, followed by
transfection with HIV-1 Tat plasmid. The levels of p-c-jun were measured after 6 hours of transfection. A representative Western blot is shown in
panels (e) and (f). Each experiment was done at least in triplicate and each bar represents the ± SE of three individual experiments. Statistical
analyses was performed by one-way ANOVA and ** denotes P-value of ≤ 0.01.
Figure 6 HIV-1 Tat-mediated expression of IL-6 and IL-8 involves activator protein-1 (AP-1) transcription factor. (a-d) Astrocytes were
transfected with either scrambled or C/EBPα or C/EBPγ or AP-1 siRNA for a duration of 48 hours, followed by either mock transfection or transfection
with HIV-1 Tat plasmid. (a, b) The expression levels of IL-6 and IL-8 at mRNA were determined by real time RT-PCR at 6 hours post transfection. The values
represented are normalized to their mock-transfected controls. (c, d) Multiplex cytokine assay was employed to measure the protein concentrations of IL-6
and IL-8 in the cell culture supernatants at 48 hours post transfection. Each experiment was done at least in triplicate and each bar represents the ± SE of
three individual experiments. Statistical analyses was performed by one-way ANOVA and ** denotes P-value of≤ 0.01.
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Figure 7 Involvement of C-Jun N-terminal kinase/mitogen-activated protein kinase (JNK MAPK) in HIV-1 Tat-mediated expression of
IL-8. (a-f) SVG astrocytes were pretreated with JNK MAPK inhibitor (SP600125) for 1 hour prior to transfection. (a, b) The expression levels of IL-6
and IL-8 at mRNA level were determined at 6 hours post transfection by real time RT-PCR. The values represented are normalized to their
mock- transfected controls. (c, d) IL-6 and IL-8 protein concentrations in the cell culture supernatants at 48 hours post transfection were
determined by multiplex cytokine assay. (e) Astrocytes were either mock-transfected or transfected with HIV-1 Tat plasmid for duration of 6
hours and p-JNK and JNK were measured in whole cell extracts. (f) The levels of p-c-jun were measured in whole cell extracts 6 hours after
the transfection. (g) Astrocytes were transfected with JNK1 siRNA for 48 hours, followed by transfection with HIV-1 Tat plasmid. The levels of
p-c-jun were measured after 6 hours of transfection. A representative Western blot is shown in the panels (e), (f) and (g). Each experiment
was done at least in triplicate and each bar represents the ± SE of three individual experiments. Statistical analyses was performed by one-way ANOVA
and ** denotes P-value of≤ 0.01.
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pro-inflammatory cytokines including IL-6, IL-8, and
IFN-γ have been found in the various regions of the brain
in HIV infected people [33-35]. Particularly, elevated levels
of IL-6 and IL-8 have been shown to play an important
role in many inflammatory responses such as recruitment
of leukocytes, accumulation of neutrophils and production
of acute phase proteins [36,37]. Viral proteins, espe-
cially HIV-1 Tat and gp120, have been implicated in
this phenomenon. Previous studies have shown the up-
regulation of IL-6 and IL-8 by HIV-1 Tat in astrocytes
[24,38]. However, very little is known about the mo-
lecular mechanisms behind the up-regulation of these
cytokines. In the present study, we sought to dissect
the molecular mechanisms behind the up-regulation of
IL-6 and IL-8 cytokines by HIV-1 Tat in SVG astrocytes.
The astrocytes were transfected with an expression plas-
mid encoding HIV-1 Tat and the expression levels of IL-6
and IL-8 were determined at various time points. The re-
sults showed a time-dependent increase in the expression
of IL-6 and IL-8 at the level of mRNA and protein. These
results are in agreement with the previous literature show-
ing the over-expression of IL-6 and IL-8 induced by HIV-
1 Tat [24,39]. However, the secretion of IL-6 was different
compared to that shown in the previous studies [39]. This
can be attributed to the difference in the type of cell line
used (CRT-MG versus SVG astrocytes) and also different
methods of HIV-1 Tat exposure (protein treatment versus
transfection). However, the expression of IL-8 at protein
level was consistent to that obtained by Kutch et al.,
where they demonstrated increased IL-8 protein expres-
sion with HIV-1 Tat protein treatment in primary astro-
cytes [24]. Our results with immunocytochemistry also
confirm the elevated presence of IL-6 and IL-8 in HIV-1
Tat-transfected astrocytes. In our studies we transfected
SVG astrocytes in most of the experiments whereas pri-
mary astrocytes were treated with recombinant protein.
The transfection reflects the effect of ongoing infection
whereas exogenous exposure reflects the effect of protein
produced by same or other cells.
NF-κB is a major transcription factor involved in regu-
lating the expression of many cytokines and chemokines.It binds to the promoter region of many genes, including
IL-6 and IL-8 to regulate their expression [40]. Previous
studies have shown increased binding and activation of
NF-κB by HIV-1 Tat in various cells, including astrocytes
and microglia [28,41]. A recent study by Fiume and co-
workers has shown that HIV-1 Tat increased the binding
of p65 DNA and also its transcriptional activity [42]. In
agreement with these reports, we have also observed a
time-dependent increase in the translocation of p65 into
the nucleus by HIV-1 Tat in SVG astrocytes. Next, we
demonstrated the involvement of NF-κB in the up-
regulation of IL-6 and IL-8 by pretreating the astrocytes
with BAY 11-7082, a specific inhibitor of IκB kinase 2
(IKK2). To confirm the data with the pharmacological
inhibitor, we have employed the siRNA approach. NF-
κB is comprised of different subunits of which p65 and
p50 are important in regulating the expression of sev-
eral cytokines/chemokines. The transcriptional activity
is mainly attributed to the p65 subunit of NF-κB [43].
The 2 subunits were knocked down individually by
using siRNA and expression of IL-6 and IL-8 were mea-
sured. Knock down of p65 but not p50 decreased the
expression levels of both IL-6 and IL-8 in astrocytes by
HIV-1 Tat. This suggests the possibility that p65 homo-
dimers are more important in regulating the expression
of IL-6 and IL-8 from astrocytes by HIV-1 Tat. This is
in agreement with the findings by Georganas and co-
workers showing that p65 homodimers but not p50
homodimers are important in regulating the expression
of both IL-6 and IL-8 in rheumatoid arthritis fibroblast-
like synoviocytes [44]. Surprisingly, knock down of p50
increased the expression levels of IL-8 at the mRNA
and protein level. This can be attributed to the role of
p50 homodimer as transcriptional repressor [45]. There-
fore, it seems that HIV-1 Tat does not use p50 homodimer
for up-regulating the expression of IL-8. However, further
investigation needs to be done to determine the role of
p50 homodimer on the expression of IL-8.
After determining the role of NF-κB, we sought to
look at the role of upstream signaling molecules that can
lead to up-regulation of IL-6 and IL-8 by HIV-1 Tat.
MAPKs are important upstream signaling molecules that
Figure 8 (See legend on next page.)
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Figure 8 HIV-1 Tat-mediated expression of IL-6 and IL-8 involves PI3K/Akt pathway. (a-f) Astrocytes were pretreated with a specific PI3K
inhibitor (LY294002) for 1 hour prior to transfection. (a, b) The expression levels of IL-6 and IL-8 at the level of mRNA were determined at 6 hours
post transfection by real time RT-PCR. The values represented are normalized to their mock-transfected controls. (c, d) IL-6 and IL-8 protein
concentrations in the cell culture supernatants at 48 hours post transfection were determined by multiplex cytokine assay. (e) Astrocytes were
either mock-transfected or transfected with HIV-1 Tat plasmid for duration of 6 hours and p-Akt levels were measured in whole cell extracts. (f)
Astrocytes were transfected for a duration of 6 hours and translocation of p65 was measured. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and LaminB were used as internal loading controls for cytoplasmic and nuclear protein fractions, respectively. A representative Western blot
is shown in figures (e) and (f). (g-j) Astrocytes were transfected with either scrambled or Akt1 or Akt2 or Akt3 siRNA for a duration of 48 hours,
followed by either mock transfection or transfection with HIV-1 Tat plasmid. (g, h) The levels of IL-6 and IL-8 at mRNA level were determined by real
time RT-PCR at 6 hours post transfection. (i, j) The protein concentrations of IL-6 and IL-8 in cell culture supernatants at 48 hours post transfection were
determined by multiplex cytokine assay. Each experiment was done at least in triplicate and each bar represents the ± SE of three individual
experiments. Statistical analyses was performed by one-way ANOVA and ** denotes P-value of≤ 0.01 and * denotes P-value of≤ 0.05.
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through NF-κB. Particularly, p38 MAPK, belonging to
the family of serine/threonine protein kinases has been
shown to be involved in the up-regulation of many cyto-
kines/chemokines [46]. The involvement of p38 MAPK
in the up-regulation of IL-6 and IL-8 by HIV-1 Tat was
determined by pretreating the astrocytes with SB203580,
a specific inhibitor of p38 MAPK. p38 MAPK exists in
four different isoforms (α/β/γ/δ), of which SB203580Figure 9 Schematic of signaling pathways involved in HIV-1 Tat-medi
signaling pathways involved in HIV-1 Tat-mediated up-regulation of IL-6 ar
AP-1 (solid line). Induction of IL-8 by HIV-1 Tat involves PI3K/Akt, p38 and C
signaling pathways, leading to the activation of NF-κB and AP-1 transcriptio
indicated by a green color whereas drug targets are indicated by a blue co
molecule is indicated by a dark color and a pale color, respectively. Specific
red color.inhibits the p38α and p38β isoforms [47]. Both these
isoforms lead to the activation of NF-κB [48]. To verify
the involvement of NF-κB activation (p38α and p38β
isoforms) and the role of other two isoforms (p38γ and
p38δ) in the up-regulation of IL-6 and IL-8 by HIV-1
Tat, we have individually knocked down all the isoforms
using siRNA. Consistent with the results of SB203580,
knock down of p38β but not p38α partially decreased the
expression levels of IL-6 and IL-8. The decrease in theated up-regulation of IL-6 and IL-8 in astrocytes. The major
e PI3K/Akt and p38 MAPK which lead to the activation of NF-κB and
-Jun N-terminal kinase/mitogen activated-protein kinase (JNK MAPK)
n factors (broken line). The siRNAs used to target various isoforms are
lor. The involvement and absence of a particular isoform or a signaling
inhibitors used for targeting signaling molecules are indicated by a
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pretreatment demonstrated the connection between p38
MAPK and NF-κB. Specifically, decrease in the transloca-
tion of p65 upon knock down of p38β shows that this
isoform is more important for the activation of NF-κB by
HIV-Tat. As knock down of p38δ partially reduced the
expression levels of IL-6 and it does not lead to the activa-
tion of NF-κB, we wanted to determine the role of various
other transcription factors that can be activated by it.
p38δ activation is associated with increased activation of
various transcription factors, including AP-1, C/EBPα and
C/EBPγ [49]. Our results demonstrated that knock down
of c-jun (important component of AP-1) but not C/EBPα
and C/EBPγ has partially decreased the expression levels
of IL-6. The Western blot showing a decrease in the
phosphorylation of c-jun by HIV-1 Tat upon knock
down of the p38δ isoform demonstrates that this
isoform is important in HIV-1 Tat-mediated expression
of IL-6.
As p38δ knock down did not alter the expression
levels of IL-8 mediated by HIV-1 Tat, we were surprised
to see the decreased expression levels of IL-8 by HIV-1
Tat upon knock down of AP-1. Then we tested the pos-
sibility of other upstream signaling molecules that can
activate c-jun to induce the expression levels of IL-8 by
HIV-1 Tat. Several previous studies have shown the role
of JNK MAPK in the activation of c-jun [50]. JNK belongs
to the family of MAPK and is involved in the activation of
transcription factors in response to various stimuli. We
demonstrated the role of JNK MAPK in the expression of
IL-8 by HIV-1 Tat by pretreatment with SP600125, a
specific inhibitor of JNK. It acts by competing with ATP
to inhibit the phosphorylation of c-jun. Pretreatment of
astrocytes with SP600125 and also siRNA against JNK has
decreased the phosphorylation levels of c-jun by HIV-1
Tat. These results unequivocally demonstrate that JNK
MAPK is important in the expression of IL-8 mediated by
HIV-1 Tat.
PI3K/Akt is a major signaling molecule that can
modulate the activation of NF-κB by promoting the
phosphorylation of IκBα [51]. Several previous studies
have indicated the role for HIV-1 and HIV-1 Tat in the
activation of PI3K/Akt pathway in macrophages [52,53].
In our study, pretreatment of SVG astrocytes with the
reversible PI3K inhibitor, LY294002, decreased HIV-1 Tat-
mediated increase in the phosphorylation of PI3K. It also
partially decreased HIV-1 Tat-mediated increase in IL-6
and IL-8. Akt or protein kinase B is a downstream signal-
ing molecule of PI3K. It belongs to the family of serine/
threonine protein kinases and is known to exist in three
different isoforms (Akt1/PKBα, Akt2/PKBβ, Akt3/PKBγ).
All three isoforms of Akt are present in the brain and
differ in their phosphorylation sites [54]. In our study,
individual knock down of all the isoforms by siRNA hasdecreased the expression levels of IL-6 and IL-8 mediated
by HIV-1 Tat. These findings indicate the importance
of all the isoforms in the expression of IL-6 and IL-8
mediated by HIV-1 Tat.Conclusions
In conclusion, we have demonstrated that HIV-1 Tat
induces the expression of IL-6 and IL-8 in astrocytes in
a time-dependent manner at both mRNA and protein
level. We demonstrated the involvement of various up-
stream signaling molecules, including PI3K/Akt, p38
MAPK and JNK MAPK by the use of pharmacological
inhibitors and gene knock down using siRNA. We have
similarly shown the activation of various transcription
factors (NF-κB and AP-1) for HIV-1 Tat-mediated in-
duction of IL-6 and IL-8 (Figure 9). As elevated levels
of pro-inflammatory cytokines are implicated in the
pathogenesis of HAND, blocking them presents a thera-
peutic intervention.Additional file
Additional file 1: Figure S1. HIV-1 Tat mediated up-regulation of p-c-jun
in SVG astrocytes and primary astrocytes: (A) SVG astrocytes were either
mock-transfected or transfected with HIV-1 Tat plasmid and p-c-jun protein
levels were measured at 3, 6, 9 and 12 hours. Each experiment was done at
least in triplicate and each bar represents the mean ± SE of three individual
experiments. (B) Primary astrocytes were treated with 200 ng/mL Tat protein
and p-c-jun protein levels were measured from 0 minutes to 60 minutes.
The blot shown in Figure 3b was re-probed with p-c-jun antibody and the
same GAPDH from Figure 3b is shown here. The bar graph represents the
mean values obtained from two independent donors. Statistical analyses
was performed by one-way ANOVA and ** denotes P-value of≤ 0.01 and
* denotes P-value of≤ 0.05.Abbreviations
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neurocognitive disorders; HIV-1 Tat: HIV-1 trans activator of transcription;
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kinase kinase; IL: interleukin; IFN: interferon; JNK: C-Jun N-terminal kinase;
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